VETMEDIN® (pimobendan) is indicated for the delay of onset of congestive heart failure in dogs with Stage B2 preclinical myxomatous mitral valve disease. Stage B2 preclinical myxomatous mitral valve disease (MMVD) refers to dogs with asymptomatic MMVD with cardiomegaly that have a moderate or loud mitral murmur due to mitral regurgitation and cardiomegaly.

VETMEDIN® (pimobendan) is indicated for the management of the signs of mild, moderate, or severe congestive heart failure (CHF) in dogs due to clinical MMVD or dilated cardiomyopathy (DCM). VETMEDIN is indicated for use with concurrent therapy for congestive heart failure (e.g., furosemide, etc.) as appropriate on a case-by-case basis.

VETMEDIN^® Brand Products feature a mode of action that acts as both a positive inotrope and potent, balanced vasodilator, simultaneously dilating veins and arteries. In these forms, the product enters the GI tract and is rapidly absorbed.

• Proprietary formulations ensures optimal bioavailability that in turn ensures optimal therapeutic effect.
   
• In a study, dogs diagnosed with Stage B2 MMVD that were treated with VETMEDIN demonstrated an average of up to 15.6 months of prolonged, symptom-free life compared to dogs treated with a placebo.
   
• In clinical studies in dogs in CHF, the dual mode of action demonstrated increased survival time and improved quality of life compared to ACE inhibitors.^{2, 3}
   
• Published evidence shows improved clinical parameters and reduced heart size when compared to dogs with CHF on ACE inhibitors.⁵
   
• Recommended by American College of Veterinary Internal Medicine (ACVIM) Specialty of Cardiology consensus panel guidelines as part of first-line therapy in dogs diagnosed with heart failure to ensure optimal patient outcomes.⁶
   
• The ACVIM recommends pimobendan, the active ingredient in VETMEDIN, for the treatment of dogs with Stage B2 MMVD.⁶
   
• The beef-flavored chewable tablet ensures high levels of acceptability that in turn promotes compliance.^{8, 9}
   
• The oral solution formulation makes it easy to give dogs who prefer liquid medication.
   
• Meets FDA standards of product efficacy, stability, and strength.

Contraindications: Do not administer VETMEDIN in cases of hypertrophic cardiomyopathy, aortic stenosis, or any other clinical condition where an augmentation of cardiac output is inappropriate for functional or anatomical reasons.

Do not administer VETMEDIN to dogs with Stage A or B1 preclinical MMVD due to the risk of cardiac pathology associated with exaggerated hemodynamic responses to VETMEDIN.

Warnings: Only for use in dogs with Stage B2 preclinical Myxolmatous Mitral Valve Disease (MMVD) or clinical evidence of Congestive Heart Failure (CHF) due to MMVD or Dilated Cardiomyopathy (DCM). At 3 and 5 times the recommended dosage, administered over a 6-month period of time, pimobendan caused an exaggerated hemodynamic response in the normal dog heart, which was associated with cardiac pathology. Keep VETMEDIN in a secure location out of reach of dogs, cats, and other animals to prevent accidental ingestion or overdose.

Human Warnings: Not for use in humans. Keep this and all medications out of reach of children. Consult a physician in case of accidental ingestion by humans.

Precautions: The safety of VETMEDIN has not been established in dogs with asymptomatic heart disease or in heart failure caused by etiologies other than myxomatous mitral valve disease (MMVD) or dilated cardiomyopathy (DCM). The safe use of VETMEDIN has not been evaluated in dogs younger than 6 months of age, dogs with congenital heart defects, dogs with diabetes mellitus or other serious metabolic diseases, dogs used for breeding, or pregnant or lactating bitches.

Adverse Reactions: The most common side effects reported in field studies were poor appetite, lethargy, diarrhea, dyspnea, azotemia, weakness, and ataxia. 

For more information, please see full prescribing information for Solution, or full prescribing information for Chewable Tablets.